Alemtuzumab mediates the CD39 + T‐regulatory cell response via CD23 + macrophages-Reference-Cited by-同舟云学术

Alemtuzumab mediates the CD39 + T‐regulatory cell response via CD23 + macrophages

Published:2021-02-10 Issue:5 Volume:99 Page:521-531
ISSN:0818-9641
Container-title:Immunology & Cell Biology
language:en
Short-container-title:Immunol. Cell Biol.

Author:

Remez Lital¹,Ganelin‐Cohen Esther²³,Safina Dina¹^ORCID,Hellmann Mark A³⁴,Lotan Itay³⁴,Bosak Noam⁵,Buxbaum Chen⁵,Vaknin Adi⁶,Shifrin Alla⁵,Rozenberg Ayal¹⁵

Affiliation:

1. Neuroimmunology Laboratory Department of Neurology Rambam Health Care Campus Haifa Israel

2. Neuroimmunological Clinic, Institute of Pediatric Neurology Schneider Children's Medical Center of Israel Petah Tikva Israel

3. Sackler School of Medicine Tel Aviv University Tel Aviv Israel

4. Department of Neurology Rabin Medical Center Beilinson Hospital Petah Tikva Israel

5. Department of Neurology Rambam Health Care Campus Haifa Israel

6. Unit for Neuro‐Immunology, Multiple Sclerosis & Cell Therapy Department of Neurology Hadassah Medical Center Jerusalem Israel

Funder

Sanofi

Publisher

Wiley

Subject

Cell Biology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/imcb.12431

Reference36 articles.

1. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond

2. Alemtuzumab CARE-MS I 5-year follow-up

3. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

4. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

5. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of COVID‐19 vaccination on multiple sclerosis activity as reflected by MRI;Brain and Behavior;2024-06-28

2. Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice;International Immunopharmacology;2023-12

3. The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis;Frontiers in Immunology;2022-07-28